Drugs / ORIC-944
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05413421 | Jun 2022 → Jun 2027 expected | metastatic prostate carcinoma | ORIC Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORIC-944 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05413421 ↗ |
| Action | Inhibit | “small molecule inhibitor of PRC2” NCT05413421 ↗ |
| Modality | Small molecule | “ORIC-944 is a potent, highly selective, allosteric, orally bioavailable, small molecule inhibitor of PRC2 via binding the embryonic ectoderm development (EED) subunit.” NCT05413421 ↗ |
| Route | Oral | “Oral, once daily, continuous” NCT05413421 ↗ |
| Target | EED | “ORIC-944 is a potent, highly selective, allosteric, orally bioavailable, small molecule inhibitor of PRC2 via binding the embryonic ectoderm development (EED) subunit.” NCT05413421 ↗ |